Orphazyme A/S
Company announcement                                                                                       

No. 26/2020                                                                                                         
Company Registration No. 32266355


Copenhagen, Denmark, March 11, 2020 – Pursuant to the Market Abuse Regulation article 19, Orphazyme A/S, CVR no. 32266355 (“Orphazyme”), hereby notifies receipt of information of the following transactions in Orphazyme’s shares by persons discharging managerial responsibilities in Orphazyme:

1 Details of the Reporting Person / Closely Associated Person
a) Name
Bo Jesper Hansen
Reason for the notification
a) Position/status
Deputy Chairman of the Board of Directors
b) Initial notification/Amendment
Initial notification
3 Details of the Company, emission allowance market participant, auction platform, auctioneer or auction monitor
a) Name
Orphazyme A/S
b) LEI code
54930025OZD2GGSQ7L42
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument and identification code
Shares
ISIN DK0060910917
b) Nature of the transaction
Purchase of shares
c) Price(s) and volume(s)

Price(s) Volume(s)
 DKK100.75250
 DKK100.75644
 DKK101.0016,000
 DKK101.005,205
 DKK101.0016
 DKK101.00500
 DKK101.00269
 DKK101.00259
 DKK101.00250
 DKK101.00100
 DKK101.00280
 DKK101.0050
 DKK101.00157
 DKK101.0069
DKK101.00138
 DKK101.002,500
 DKK101.0069
 DKK101.00240
 DKK101.0020
 DKK101.00137
 DKK101.00200
 DKK101.00250
 DKK101.004,000
 DKK101.00200
 DKK101.004,416
 DKK101.003,182
 DKK101.00250
 DKK101.0069
 DKK101.50140
 DKK102.00140

d) Aggregated information
Aggregated volume: 40,000
Aggregated price: DKK 4,039,986.50
Price per share (volume weighted average): DKK 100.9996625
e) Date of the transaction
11 March 2020 between 12:12 and 14:10 UTC
f) Place of the transaction
Nasdaq Copenhagen A/S – XCSE and DCSE


For additional information, please contact

Orphazyme A/S

Anders Vadsholt, CFO                                  +45 28 98 90 55


About Orphazyme A/S 
Orphazyme is a biopharmaceutical company focused on bringing novel treatments to patients living with life-threatening or debilitating rare diseases. Our research focuses on developing therapies for diseases caused by misfolding of proteins, including lysosomal storage diseases. Arimoclomol, the company’s lead candidate, is in clinical development for four orphan diseases: Niemann-Pick disease Type C, Gaucher disease, sporadic Inclusion Body Myositis, and Amyotrophic Lateral Sclerosis. The Denmark-based company is listed on Nasdaq Copenhagen (ORPHA.CO). For more information, please visit www.orphazyme.com

Forward-looking statement 
This company announcement may contain certain forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this company announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “aim,” “intend,” “may,” “anticipate,” “estimate,” “plan,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could”, and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.  

Attachment